The report for Mrs. Yam Kumari Sigdel, an 87-year-old female, indicates a negative result for HER2 amplification based on FISH testing, which suggests she is not eligible for anti-HER2 therapy. The clinical interpretation confirms that the HER2/CEP17 ratio is below 2, aligning with ASCO 2018 guidelines. The report emphasizes the importance of further testing in cases of tumor heterogeneity for conclusive results.
The report for Mrs. Yam Kumari Sigdel, an 87-year-old female, indicates a negative result for HER2 amplification based on FISH testing, which suggests she is not eligible for anti-HER2 therapy. The clinical interpretation confirms that the HER2/CEP17 ratio is below 2, aligning with ASCO 2018 guidelines. The report emphasizes the importance of further testing in cases of tumor heterogeneity for conclusive results.
The report for Mrs. Yam Kumari Sigdel, an 87-year-old female, indicates a negative result for HER2 amplification based on FISH testing, which suggests she is not eligible for anti-HER2 therapy. The clinical interpretation confirms that the HER2/CEP17 ratio is below 2, aligning with ASCO 2018 guidelines. The report emphasizes the importance of further testing in cases of tumor heterogeneity for conclusive results.
The report for Mrs. Yam Kumari Sigdel, an 87-year-old female, indicates a negative result for HER2 amplification based on FISH testing, which suggests she is not eligible for anti-HER2 therapy. The clinical interpretation confirms that the HER2/CEP17 ratio is below 2, aligning with ASCO 2018 guidelines. The report emphasizes the importance of further testing in cases of tumor heterogeneity for conclusive results.
Age/DOB/Sex : 87 Years / / Female Hospital Name : N.P.L. Kathmandu Private Limited, Kathmandu Physician Name : DR PRAKASH SAYANI Regn Date : 15-Jan-2025 09:06 Collection On : 13-Jan-2025 00:00 Reported On : 20-Jan-2025 16:48 Process AT : CORE-Gurugram MC-2256 Ref no : Sample Type : FFPE Block UNIQUE PATIENT ID: 343596 Report Status : Final
TEST NAME HER2 SPECIMEN INFORMATION Labelled as 2097/24 CLINICAL HISTORY Invasive carcinoma. METHODOLOGY Fluorescence In Situ Hybridization
DIAGNOSIS FISH MARKER Result
HER2 (FISH) Negative
Total number of cells scored 100
Total number of HER2 signals 425
Total number of CEP17 signals 240
Average HER2 signals/cells 4.25
Computed Ratio 1.77
Probe used: HEALTHCARE HER2/CEP17 dual color probe. HER2: Orange, CEP17: Green
CLINICAL INTERPRETATION 1. As the Her2/neu IHC is 2+ the sample is Negative for HER2/neu amplification as per ASCO 2018 guideline 2. Her2:CEP17 ratio is <2 and Average Her2 signals 4-6 (Group 4).
Dr. Shivani Sharma Dr.Sonika
DCP, DNB, DipRCPath. Ph.D Reg. No. 1906 Page 1 of 2 Case ID : 25010008735 Patient Name : Mrs. YAM KUMARI SIGDEL Age/DOB/Sex : 87 Years / / Female Hospital Name : N.P.L. Kathmandu Private Limited, Kathmandu Physician Name : DR PRAKASH SAYANI Regn Date : 15-Jan-2025 09:06 Collection On : 13-Jan-2025 00:00 Reported On : 20-Jan-2025 16:48 Process AT : CORE-Gurugram MC-2256 Ref no : Sample Type : FFPE Block UNIQUE PATIENT ID: 343596 Report Status : Final
COMMENTS 1. Evaluation of this specimen shows a normal hybridization pattern. These findings are indicative that the patient is not eligible for anti HER2 therapy (Trastuzumab). 2. Her2 gene amplification is seen 18 to 20% of invasive breast cancers. These tumours show increased over all survival rate with Her2 targeted therapy such as Trastuzumab. 3. It has been recognised as a poor prognosis indicator in early breast cancer. 4. In cases where tumor heterogeneity is present, analysis of HER2 FISH on additional blocks is recommended for conclusive result. REFERENCES 1.Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists clinical Practice Guideline Focused Update 2. Antonio C. Wolff, M. Elizabeth Hale Hammond, Kimberly H. Allison, Brittany E. Harvey, Pamela B. Mangu, John M.S. Bartlett, Michael Bilous, Ian O. Ellis, Patrick Fitzgibbons, Wedad Hanna, Robert B. Jenkins, Michael F. Press, Patricia A. Spears, Gail H. Vance, Giuseppe Viale, Lisa M. McShane, and Mitchell Dowsett Journal of Clinical Oncology 2018 36:20, 2105-2122 Disclaimer: • Testing only validated for FFPE specimens; specimens fixed in other than 10% neutral buffered formalin have not been validated using this method. Fixation time should not be less than 6 hours and not more than 72 hours for FISH testing. • Specimens placed in decalcifying solution may have a false-negative result. • This test is not FDA approved / cleared for specific uses. • Repeat testing is recommended for discordant results.
Dr. Shivani Sharma Dr.Sonika
DCP, DNB, DipRCPath. Ph.D Reg. No. 1906 Page 2 of 2 II Scan to Connect
If you have any ques ons about this report or would like to have a conversa on about the test results, please feel free to reach out to us at
+91 88828 99999 or info@corediagnos cs.in
CONDITIONS OF REPORTING 1. The tests are carried out in the lab with the presump on that the specimen belongs to the pa ent named or iden fied in the bill/test request form. 2. The test results relate specifically to the sample received in the lab and are presumed to have been generated and transported per specific instruc ons given by the physicians/laboratory. 3. The reported results are for informa on and are subject to confirma on and interpreta on by the referring doctor. 4. Some tests are referred to other laboratories to provide a wider test menu to the customer. 5. CORE Diagnos cs Pvt. Ltd. shall in no event be liable for accidental damage, loss, or destruc on of specimen, which is not a ributable to any direct and mala fide act or omission of CORE Diagnos cs Pvt. Ltd. or its employees. Liability of CORE Diagnos cs Pvt. Ltd. for deficiency of services, or other errors and omissions shall be limited to fee paid by the pa ent for the relevant laboratory services.
This report is the property of CORE Diagnos cs. The informa on contained in this report is strictly confiden al and is only for the use of those authorized. If you have received this report by mistake, please contact CORE Diagnos cs
406, Udyog Vihar, Phase III, Gurugram, Haryana ‐ 122016 T.: +91 8882899999
CōRE Diagnos cs Satellite Lab ‐ New Delhi
C‐13, 1st Floor, Green Park Extension, New Delhi ‐ 110016 I T.: 011 46269604 67, Hargobind Enclave, New Delhi ‐ 110092 I T.: +91 9318333855 H64, Block H, Bali Nagar, New Delhi ‐ 110015 I T.: 011‐41504265
